Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer

NCT04925986 is registered in ClinicalTrials.gov with Sarah Goldberg as lead sponsor.

NCT NCT04925986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04925986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
Sarah Goldberg
Phase
Phase 2
Overall status
Terminated
Start date
February 10, 2022
Completion date
October 30, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced treatment-naïve pd-l1, carcinoma, non-small-cell lung, lung diseases, lung neoplasms, metastatic lung non-small cell carcinoma, pd-l1 gene mutation, pembrolizumab, sitravatinib, stage iv lung non-small cell cancer ajcc v7